Rivian Automotive expects factors like a lower average selling price of its cars to dent its second-quarter revenue, a week after the electric vehicle maker reported deliveries for the quarter that topped its own forecast. The company said it expects revenue to increase in the quarter from a year ago due to an increase in vehicle deliveries, but that growth will be partially offset by a lower average selling price from a higher mix of commercial vans, as well as increases in vehicle electrical architecture and software development services and revenues related to regulatory credits. The stock fell 8.9% to $18.34 in after-hours trading.

Turn Therapeutics said it would present initial findings from a Phase 2 trial of GX-03, its treatment for atopic dermatitis, on a Tuesday webcast. The company said it would also share an optimized study design for the remaining stage of the phase 2 trial. Shares were up 2.9% in late trading before paring those gains, and were recently flat after hours.

Globavend said all of its outstanding Series A warrants expired in accordance with their terms, eliminating a potential source of future shareholder dilution. The company said the expiration of the warrants, which were issued in connection with its June 2025 public offering, simplifies its capital structure. Globavend said it now has no outstanding warrants. Shares were up 2.5% at $3.76 after hours.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

July 06, 2026 19:13 ET (23:13 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.